Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Bitan, Menachem ^a,d   Weiss, Lola ^a   Zeira, Michael ^a   Zcharia, Eyal ^a   Slavin, Shimon ^a   Nagler, Arnon ^b   Vlodavsky, Israel ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPARANASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BETA GLUCURONIDASE; CYTOKINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HAIR LOSS; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MALE; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PROTECTION; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE; TRANSGENIC MOUSE; WEIGHT REDUCTION; ANIMAL; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; DRUG EFFECT; GRAFT SURVIVAL; IMMUNOLOGY; METHODOLOGY; MOUSE STRAIN; SURVIVAL RATE;

MUS; MUS MUSCULUS;

ANIMALS; BONE MARROW TRANSPLANTATION; CYTOKINES; GLUCURONIDASE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 77956336184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010135     Document Type: Article

References (67)

1. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, et al. (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-777.
2. Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest 108: 169-173.
3. Gallagher JT (2001) Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 108: 357-361.
4. Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67: 609-652.
5. Vlodavsky I, Bar-Shavit R, Korner G, Fuks Z (1993) Extracellular matix-bound growth factors, enzymes and plasma proteins. In: Academic press Inc., Basement membranes: Cellular and molecular aspects. Orlando, Fl: D.H. Rohrbach and R. Timpl (eds). pp 327-343.
6. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379.
7. Dempsey LA, Plummer TB, Coombes SL, Platt JL (2000) Heparanase expression in invasive trophoblasts and acute vascular damage. Glycobiology 10: 467-475.
8. Ferro V, Hammond E, Fairweather JK (2004) The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 4: 693-702.
9. Ilan N, Elkin M, Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38: 2018-2039.
10. McKenzie EA (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151: 1-14.
11. Parish CR, Freeman C, Hulett MD (2001) Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471: M99-108.
12. Sanderson RD, Yang Y, Suva LJ, Kelly T (2004) Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol 23: 341-352.
13. Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108: 341-347.
14. Vreys V, David G (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11: 427-452.
15. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, et al. (2006) Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107: 3609-3616.
16. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, et al. (2001) Heparanase as mediator of angiogenesis: mode of action. Faseb J 15: 1661-1663.
17. Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H, et al. (2002) Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 99: 10031-10036.
18. Abboud-Jarrous G, Atzmon R, Peretz T, Palermo C, Gadea BB, et al. (2008) Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem.
19. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H, Atzmon R, Elgavish S, et al. (2005) Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 280: 13568-13575.
20. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N (2003) Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 308: 885-891.
21. McKenzie E, Young K, Hircock M, Bennett J, Bhaman M, et al. (2003) Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373: 423-435.
22. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, et al. (2004) Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43: 1862-1873.
23. Li RW, Freeman C, Yu D, Hindmarsh EJ, Tymms KE, et al. (2008) Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 58: 1590-1600.
24. Naparstek Y, Cohen IR, Fuks Z, Vlodavsky I (1984) Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 310: 241-244.
25. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, et al. (1992) Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12: 112-127.
26. Barrett AJ (1997) Mechanisms of the graft-versus-leukemia reaction. Stem Cells 15: 248-258.
27. Bortin MM, Rimm AA, Saltzstein EC (1973) Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science 179: 811-813.
28. Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29: 259-277.
29. Ferrara JL, Deeg HJ (1991) Graft-versus-host disease. N Engl J Med 324: 667-674.
30. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, et al. (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102: 756-762.
31. Spiegel A, Zcharia E, Vagima Y, Itkin T, Kalinkovich A, et al. (2008) Heparanase regulates retention and proliferation of primitive Sca-1+/c-Kit+/Lin- cells via modulation of the bone marrow microenvironment. Blood 111: 4934-4943.
32. Bitan M, Weiss L, Zeira M, Reich S, Pappo O, et al. (2008) Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production. Diabetes Metab Res Rev 24: 413-421.
33. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE (1994) Donor CD4- enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84: 3540-3549.
34. Rus V, Svetic A, Nguyen P, Gause WC, Via CS (1995) Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graftversus- host disease. Regulatory role of donor CD8+ T cells. J Immunol 155: 2396-2406.
35. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S, et al. (1997) The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant 19: 571-576.
36. Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80: 2964-2968.
37. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, et al. (1990) Increase serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75: 1011-1016.
38. Nagler A, Bishara A, Brautbar C, Barak V (1998) Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation. Cytokines Cell Mol Ther 4: 161-167.
39. Zecchina G, Novick D, Rubinstein M, Barak V, Dinarello C, et al. (2001) Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. J Hematother Stem Cell Res 10: 769-776.
40. Zcharia E, Metzger S, Chajek-Shaul T, Aingorn H, Elkin M, et al. (2004) Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. Faseb J 18: 252-263.
41. Ilan Y, Gotsman I, Pines M, Beinart R, Zeira M, et al. (2000) Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model. Blood 95: 3613-3619.
42. Pugatsch T, Oppenheim A, Slavin S (1996) Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 17: 273-275.
43. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, et al. (2000) Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39: 15659-15667.
44. Zetser A, Bashenko Y, Miao HQ, Vlodavsky I, Ilan N (2003) Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63: 7733-7741.
45. Casu B, Guerrini M, Naggi A, Perez M, Torri G, et al. (2002) Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry 41: 10519-10528.
46. Vlodavsky I, Ilan N, Naggi A, Casu B (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13: 2057-2073.
47. Slavin S, Strober S, Fuks Z, Kaplan HS (1977) Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 146: 34-48.
48. Porgador A, Mandelboim O, Restifo NP, Strominger JL (1997) Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 94: 13140-13145.
49. Weiss L, Barak V, Zeira M, Abdul-Hai A, Raibstein I, et al. (2002) Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th(2) shift on autoimmune and anti-inflammatory processes. Cytokine 19: 85-93.
50. Pan L, Delmonte J, Jr., Jalonen CK, Ferrara JL (1995) Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graftversus- host disease. Blood 86: 4422-4429.
51. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N (2008) Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 68: 10077-10085.
52. Trinchieri G (1993) Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14: 335-338.
53. Romagnani S (1991) Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 21: 152-158.
54. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J (2003) Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versusleukemia responses. Biol Blood Marrow Transplant 9: 292-303.
55. Roy J, Blazar BR, Ochs L, Weisdorf DJ (1995) The tissue expression of cytokines in human acute cutaneous graft-versus-host disease. Transplantation 60: 343-348.
56. Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 115: 2319-2328.
57. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, et al. (2009) Structure-function approach identifies a C-terminal domain that mediates heparanase signaling. Cancer Res 69: 1758-1767.
58. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, et al. (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66: 1455-1463.
59. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, et al. (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123: 2566-2573.
60. Kim DH, Lee NY, Lee MH, Sohn SK (2008) Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant 14: 1408-1416.
61. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, et al. (2009) IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 113: 945-952.
62. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, et al. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282: 13326-13333.
63. Rops AL, Gotte M, Baselmans MH, van den Hoven MJ, Steenbergen EJ, et al. (2007) Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int 72: 1204-1215.
64. Xu J, Park PW, Kheradmand F, Corry DB (2005) Endogenous attenuation of allergic lung inflammation by syndecan-1. J Immunol 174: 5758-5765.
65. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, Ilan N (2007) Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 361: 829-834.
66. Vreys V, Delande N, Zhang Z, Coomans C, Roebroek A, et al. (2005) Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem 280: 33141-33148.
67. Ben-Zaken O, Shafat I, Gingis-Velitski S, Bangio H, Kelson IK, et al. (2008) Low and high affinity receptors mediate cellular uptake of heparanase. Int J Biochem Cell Biol 40: 530-542.